Association of Alopecia Areata With Attention-Deficit/Hyperactivity Disorder Stimulant Medication: A Case-Control Study
- PMID: 34239372
- PMCID: PMC8238113
- DOI: 10.31486/toj.20.0025
Association of Alopecia Areata With Attention-Deficit/Hyperactivity Disorder Stimulant Medication: A Case-Control Study
Abstract
Background: Both psychiatric disorders and diverse medications used to treat them have been associated with alopecia. The objective of our study was to investigate the existence of an association between attention-deficit/hyperactivity disorder (ADHD) stimulant medication (ASM) and various types of alopecia. Methods: We conducted a retrospective case-control medical record review of patients between the ages of 6 and 18 years seen in dermatology clinics during a 10-year period. Cases included patients diagnosed with alopecia areata (AA), alopecia totalis (AT), or alopecia universalis (AU). We matched 3 controls on age and sex to each case. We reviewed patients' medical records for the following medications: lisdexamfetamine, amphetamine/dextroamphetamine, dexmethylphenidate, and methylphenidate. We examined the association between medications used to treat ADHD and diagnoses of AA, AT, and/or AU by calculating a series of odds ratios and 95% CIs. Results: We identified 124 cases (110 with AA, 11 with AT, and 3 with AU) and 372 controls. We found a strong association between AU and ASM use (P<0.0071). No relationship between ASM use and other types of hair loss was found. Conclusion: Although the sample size of cases with AU was small, we found a significant association between AU and ASM. While further study is needed, practitioners may consider close monitoring of patients with AA who use ASM for the development of worsening disease and discontinue the medication if the patient experiences an increase in hair loss that appears to be progressing to AU.
Keywords: Alopecia; alopecia areata; alopecia universalis; amphetamine; attention deficit disorder with hyperactivity.
©2021 by the author(s); Creative Commons Attribution License (CC BY).
Similar articles
-
Demographic and Clinical Features of 1,641 Patients with Alopecia Areata, Alopecia Totalis, and Alopecia Universalis: A Single-Center Retrospective Study.Skin Appendage Disord. 2021 Jan;7(1):8-12. doi: 10.1159/000510880. Epub 2020 Oct 28. Skin Appendage Disord. 2021. PMID: 33614711 Free PMC article.
-
Increased Alopecia Areata Risk in Children with Attention-Deficit/Hyperactivity Disorder and the Impact of Methylphenidate Use: A Nationwide Population-Based Cohort Study.Int J Environ Res Public Health. 2021 Feb 1;18(3):1286. doi: 10.3390/ijerph18031286. Int J Environ Res Public Health. 2021. PMID: 33535410 Free PMC article.
-
Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children in a US Employer-Sponsored Insured Population.JAMA Dermatol. 2023 Apr 1;159(4):411-418. doi: 10.1001/jamadermatol.2023.0002. JAMA Dermatol. 2023. PMID: 36857069 Free PMC article.
-
Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata: A Systematic Review and Meta-analysis.JAMA Dermatol. 2018 Oct 1;154(10):1145-1151. doi: 10.1001/jamadermatol.2018.2312. JAMA Dermatol. 2018. PMID: 30073292 Free PMC article.
-
Review of treatment for alopecia totalis and alopecia universalis.Int J Dermatol. 2017 Aug;56(8):801-810. doi: 10.1111/ijd.13612. Epub 2017 Apr 5. Int J Dermatol. 2017. PMID: 28378336 Review.
References
LinkOut - more resources
Full Text Sources